Clinical Implications of Sarcopenic Obesity in Cancer

Current Oncology Reports

Volumn 18, Issue 10, 2016, Pages

  Carneiro, Isabella P ^a   Mazurak, Vera C ^a   Prado, Carla M ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Body composition; Cancer; Chemotherapy toxicity; Morbidity; Sarcopenic obesity; Survival

Indexed keywords

ANTINEOPLASTIC AGENT;

BODY COMPOSITION; BODY FAT; BODY MASS; CANCER MORTALITY; CANCER PROGNOSIS; COMPUTER ASSISTED TOMOGRAPHY; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; DUAL ENERGY X RAY ABSORPTIOMETRY; FAT MASS; HUMAN; IMPEDANCE; MALIGNANT NEOPLASTIC DISEASE; MUSCLE MASS; OBESITY; OVERALL SURVIVAL; PHYSICAL DISABILITY; POSTOPERATIVE COMPLICATION; PREVALENCE; REVIEW; RISK ASSESSMENT; SARCOPENIA; SARCOPENIC OBESITY; SURVIVAL RATE; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT; COMPLICATION; DOSE RESPONSE; NEOPLASMS; PATHOPHYSIOLOGY; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BODY COMPOSITION; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; NEOPLASMS; OBESITY; PREVALENCE; SARCOPENIA; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84983239031     PISSN: 15233790     EISSN: 15346269     Source Type: Journal    
DOI: 10.1007/s11912-016-0546-5     Document Type: Review

References (77)

1. Lieffers JR, Bathe OF, Fassbender K, Winget M, Baracos VE. Sarcopenia is associated with postoperative infection and delayed recovery from colorectal cancer resection surgery. Br J Cancer. 2012;6:931–6.
2. Kim EY, Kim YS, Park I, Ahn HK, Cho EK, Jeong YM. Prognostic significance of ct-determined sarcopenia in patients with small-cell lung cancer. J Thorac Oncol. 2015;10(12):1795–9. doi:10.1097/jto.0000000000000690.
3. Joglekar S, Asghar A, Mott SL, Johnson BE, Button AM, Clark E, et al. Sarcopenia is an independent predictor of complications following pancreatectomy for adenocarcinoma. J Surg Oncol. 2015;111(6):771–5. doi:10.1002/jso.23862.
4. Tan BH, Brammer K, Randhawa N, Welch NT, Parsons SL, James EJ, et al. Sarcopenia is associated with toxicity in patients undergoing neo-adjuvant chemotherapy for oesophago-gastric cancer. Eur J Surg Oncol. 2015;41(3):333–8. doi:10.1016/j.ejso.2014.11.040.
5. Prado CM, Baracos VE, McCargar LJ, Mourtzakis M, Mulder KE, Reiman T, et al. Body composition as an independent determinant of 5-fluorouracil-based chemotherapy toxicity. Clin Cancer Res. 2007;13(11):3264–8. doi:10.1158/1078-0432.ccr-06-3067.
6. Prado CMM, Liefers JR, McCargar LJ, Reiman T, Sawyer MB, Martin L, et al. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncology. 2008;9(7):629–35. doi:10.1016/51470-2045(08)70153-0. Although an older study, this was the first to identify sarcopenic obesity in cancer, also linking this condition with shorter survival. The cutpoints used in this study have been extensively used to define sarcopenia.
7. Prado CM, Cushen SJ, Orsso CE, Ryan AM. Sarcopenia and cachexia in the era of obesity: clinical and nutritional impact. Proc Nutr Soc. 2016;1–11. doi:10.1017/s0029665115004279.
8. Fearon KC, Von Meyenfeldt MF, Moses AG, Van Geenen R, Roy A, Gouma DJ, et al. Effect of a protein and energy dense N-3 fatty acid enriched oral supplement on loss of weight and lean tissue in cancer cachexia: a randomised double blind trial. Gut. 2003;52(10):1479–86.
9. Simons JP, Schols AM, Hoefnagels JM, Westerterp KR, ten Velde GP, Wouters EF. Effects of medroxyprogesterone acetate on food intake, body composition, and resting energy expenditure in patients with advanced, nonhormone-sensitive cancer: a randomized, placebo-controlled trial. Cancer. 1998;82(3):553–60.
10. Prado CM, Wells JC, Smith SR, Stephan BC, Siervo M. Sarcopenic obesity: a critical appraisal of the current evidence. Clin Nutr. 2012;31(5):583–601. doi:10.1016/j.clnu.2012.06.010.
11. Must A, Spadano J, Coakley EH, Field AE, Colditz G, Dietz WH. The disease burden associated with overweight and obesity. JAMA. 2015;282(16):1523–9. doi:10.1001/jama.282.16.1523.
12. Srikanthan P, Hevener AL, Karlamangla AS. Sarcopenia exacerbates obesity-associated insulin resistance and dysglycemia: findings from the National Health and Nutrition Examination Survey III. PLoS One. 2010;5(5):e10805. doi:10.1371/journal.pone.0010805.
13. Han K, Park YM, Kwon HS, Ko SH, Lee SH, Yim HW, et al. Sarcopenia as a determinant of blood pressure in older koreans: findings from the Korea National Health and Nutrition Examination Surveys (KNHANES) 2008–2010. PLoS One. 2014;9:e86902.
14. Chin SO, Rhee SY, Chon S, Hwang YC, Jeong IK, Oh S, et al. Sarcopenia is independently associated with cardiovascular disease in older korean adults: the Korea National Health and Nutrition Examination Survey (KNHANES) from 2009. PLoS One. 32013.
15. Prado CM, Lieffers JR, Bowthorpe L, Baracos VE, Mourtzakis M, McCargar LJ. Sarcopenia and physical function in overweight patients with advanced cancer. Can J Diet Pract Res. 2013;74(2):69–74. doi:10.3148/74.2.2013.69.
16. Rollins KE, Tewari N, Ackner A, Awwad A, Madhusudan S, Macdonald IA, et al. The impact of sarcopenia and myosteatosis on outcomes of unresectable pancreatic cancer or distal cholangiocarcinoma. Clin Nutr. 2015. doi:10.1016/j.clnu.2015.08.005. This study shows that in addition to muscle quantity, myosteatosis predicts prognosis. Myosteatosis is indicative of adipose tissue infiltration into the muscle, and hence poorer prognosis.
17. Lodewick TM, van Nijnatten TJA, van Dam RM, van Mierlo K, Dello SAWG, Neumann UP, et al. Are sarcopenia, obesity and sarcopenic obesity predictive of outcome in patients with colorectal liver metastases? Hpb. 2015;17(5):438–46. doi:10.1111/hpb.12373.
18. Tan BH, Birdsell LA, Martin L, Baracos VE, Fearon KC. Sarcopenia in an overweight or obese patient is an adverse prognostic factor in pancreatic cancer. Clin Cancer Res. 2009;15(22):6973–9. doi:10.1158/1078-0432.CCR-09-1525.
19. Martin L, Birdsell L, Macdonald N, Reiman T, Clandinin MT, McCargar LJ, et al. Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J Clin Oncol. 2013;31(12):1539–47. doi:10.1200/jco.2012.45.2722. This study determined BMI-specific cutpoints for sarcopenia which are extensively used in the oncology setting.
20. Reisinger KW, Derikx JP, van Vugt JL, Von Meyenfeldt MF, Hulsewe KW, Olde Damink SW, et al. Sarcopenia is associated with an increased inflammatory response to surgery in colorectal cancer. Clin Nutr. 2015. doi:10.1016/j.clnu.2015.07.005.
21. Lodewick TM, Roeth AA, Olde Damink SW, Alizai PH, van Dam RM, Gassler N, et al. Sarcopenia, obesity and sarcopenic obesity: effects on liver function and volume in patients scheduled for major liver resection. J Cachex Sarcopenia Muscle. 2015;6(2):155–63. doi:10.1002/jcsm.1201810.1002/jcsm.12018.
22. Psutka S, Boorjian S, Moynagh M, Schmit G, Stewart S, Carrasco A, et al. Sarcopenic obesity in bladder cancer: additive risks of cachexia and obesity in patients undergoing radical cystectomy? Journal of Urology. 2014;191(4):E561-E.
23. Dalal S, Hui D, Bidaut L, Lem K, Del Fabbro E, Crane C, et al. Relationships among body mass index, longitudinal body composition alterations, and survival in patients with locally advanced pancreatic cancer receiving chemoradiation: a pilot study. J Pain Symptom Manage. 2012;44(2):181–91. doi:10.1016/j.jpainsymman.2011.09.010.
24. Anandavadivelan P, Brismar TB, Nilsson M, Johar AM, Martin L. Sarcopenic obesity: a probable risk factor for dose limiting toxicity during neo-adjuvant chemotherapy in oesophageal cancer patients. Clin Nutr. 2015. doi:10.1016/j.clnu.2015.05.011.
25. Baumgartner RN, Koehler KM, Gallagher D, Romero L, Heymsfield SB, Ross RR, et al. Epidemiology of sarcopenia among the elderly in New Mexico. Am J Epidemiol. 1998;147(8):755–63.
26. Heymsfield SB, Smith R, Aulet M, Bensen B, Lichtman S, Wang J, et al. Appendicular skeletal muscle mass: measurement by dual-photon absorptiometry. Am J Clin Nutr. 1990;52(2):214–8.
27. Prado CM, Heymsfield SB. Lean tissue imaging: a new era for nutritional assessment and intervention. JPEN J Parenter Enteral Nutr. 2014;38(8):940–53. doi:10.1177/0148607114550189.
28. Shen W, Punyanitya M, Wang Z, Gallagher D, St-Onge MP, Albu J, et al. Total body skeletal muscle and adipose tissue volumes: estimation from a single abdominal cross-sectional image. J Appl Physiol (Bethesda, Md: 1985). 2004;97(6):2333–8. doi:10.1152/japplphysiol.00744.2004.
29. Mourtzakis M, Prado CM, Lieffers JR, Reiman T, McCargar LJ, Baracos VE. A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Appl Physiol Nutr Metab. 2008;33(5):997–1006. doi:10.1139/h08-075.
30. Gonzalez MC, Pastore CA, Orlandi SP, Heymsfield SB. Obesity paradox in cancer: new insights provided by body composition. Am J Clin Nutr. 2014;99(5):999–1005. doi:10.3945/ajcn.113.071399. Using a readily available tool (bioelectrical impedance analysis), this study highlighted the importance of body composition assessment to differentiate survival between sarcopenic and non-sarcopenic obese patients.
31. Kyle UG, Pirlich M, Lochs H, Schuetz T, Pichard C. Increased length of hospital stay in underweight and overweight patients at hospital admission: a controlled population study. Clin Nutr. 2005;24(1):133–42. doi:10.1016/j.clnu.2004.08.012.
32. Del Fabbro E, Parsons H, Warneke CL, Pulivarthi K, Litton JK, Dev R, et al. The relationship between body composition and response to neoadjuvant chemotherapy in women with operable breast cancer. Oncologist. 2012;17(10):1240–5. doi:10.1634/theoncologist.2012-0169.
33. Peng PD, van Vledder MG, Tsai S, de Jong MC, Makary M, Ng J, et al. Sarcopenia negatively impacts short-term outcomes in patients undergoing hepatic resection for colorectal liver metastasis. HPB. 2011;13(7):439–46. doi:10.1111/j.1477-2574.2011.00301.x.
34. Psutka SP, Boorjian SA, Moynagh MR, Schmit GD, Frank I, Carrasco A, et al. Mortality after radical cystectomy: impact of obesity versus adiposity after adjusting for skeletal muscle wasting. J Urol. 2015;193(5):1507–13. doi:10.1016/j.juro.2014.11.088.
35. Kelly TL, Wilson KE, Heymsfield SB. Dual energy X-ray absorptiometry body composition reference values from NHANES. PLoS One. 2009;4(9):e7038. doi:10.1371/journal.pone.0007038.
36. Kuroki LM, Mangano M, Allsworth JE, Menias CO, Massad LS, Powell MA, et al. Pre-operative assessment of muscle mass to predict surgical complications and prognosis in patients with endometrial cancer. Ann Surg Oncol. 2015;22(3):972–9. doi:10.1245/s10434-014-4040-8.
37. Baracos VE. Cancer-associated cachexia and underlying biological mechanisms. Annu Rev Nutr. 2006;26:435–61. doi:10.1146/annurev.nutr.26.061505.111151.
38. Baracos VE. Skeletal muscle anabolism in patients with advanced cancer. Lancet Oncol. 2015;16(1):13–4. doi:10.1016/s1470-2045(14)71185-4.
39. Prado CM, Antoun S, Sawyer MB, Baracos VE. Two faces of drug therapy in cancer: drug-related lean tissue loss and its adverse consequences to survival and toxicity. Curr Opin Clin Nutr Metab Care. 2011;14(3):250–4. doi:10.1097/MCO.0b013e3283455d45.
40. Canadian Cancer Society. 2014 edition of Canadian cancer statistics. 2014. http://www.cancer.ca/en/cancer-information/cancer-101/canadian-cancer-statistics-publication/?region=on.
41. Doyle SL, Bennett AM, Donohoe CL, Mongan AM, Howard JM, Lithander FE, et al. Establishing computed tomography-defined visceral fat area thresholds for use in obesity-related cancer research. Nutr Res (New York, NY). 2013;33(3):171–9. doi:10.1016/j.nutres.2012.12.007.
42. Huillard O, Mir O, Peyromaure M, Tlemsani C, Giroux J, Boudou-Rouquette P, et al. Sarcopenia and body mass index predict sunitinib-induced early dose-limiting toxicities in renal cancer patients. Br J Cancer. 2013;108(5):1034–41. doi:10.1038/bjc.2013.58.
43. Barret M, Antoun S, Dalban C, Malka D, Mansourbakht T, Zaanan A, et al. Sarcopenia is linked to treatment toxicity in patients with metastatic colorectal cancer. Nutr Cancer. 2014;66(4):583–9. doi:10.1080/01635581.2014.894103.
44. Antoun S, Baracos VE, Birdsell L, Escudier B, Sawyer MB. Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma. 2010. doi:10.1093/annonc/mdp605.
45. Prado CMM, Baracos VE, Xiao J, Birdsell L, Stuyckens K, Park YC, et al. The association between body composition and toxicities from the combination of doxil and trabectedin in patients with advanced relapsed ovarian cancer. Appl Physiol Nutr Metab. 2014;39(6):693–8. doi:10.1139/apnm-2013-0403.
46. Zamboni WC, Strychor S, Maruca L, Ramalingam S, Zamboni BA, Wu H, et al. Pharmacokinetic study of pegylated liposomal CKD-602 (S-CKD602) in patients with advanced malignancies. Clin Pharmacol Ther. 2009;86(5):519–26. doi:10.1038/clpt.2009.14110.1038/clpt.2009.141. Epub 2009 Aug 12.
47. van Kesteren C, de Vooght MM, Lopez-Lazaro L, Mathot RA, Schellens JH, Jimeno JM, et al. Yondelis (trabectedin, ET-743): the development of an anticancer agent of marine origin. Anticancer Drugs. 2003;14(7):487–502. doi:10.1097/01.cad.0000086304.28884.93.
48. Hunter RJ, Navo MA, Thaker PH, Bodurka DC, Wolf JK, Smith JA. Dosing chemotherapy in obese patients: actual versus assigned body surface area (BSA). Cancer Treat Rev. 2009;35(1):69–78. doi:10.1016/j.ctrv.2008.07.005.
49. Dignam JJ, Polite BN, Yothers G, Raich P, Colangelo L, O’Connell MJ, et al. Body mass index and outcomes in patients who receive adjuvant chemotherapy for colon cancer. J Natl Cancer Inst. 2006;98(22):1647–54. doi:10.1093/jnci/djj442.
50. Lopes-Serrao MD, Ussery SM, Hall 2nd RG, Shah SR. Evaluation of chemotherapy-induced severe myelosuppression incidence in obese patients with capped dosing. J Oncol Pract. 2011;7(1):13–7. doi:10.1200/jop.2010.000045.
51. Levolger S, van Vledder MG, Muslem R, Koek M, Niessen WJ, de Man RA, et al. Sarcopenia impairs survival in patients with potentially curable hepatocellular carcinoma. J Surg Oncol. 2015;112(2):208–13. doi:10.1002/jso.23976.
52. Fukuda Y, Yamamoto K, Hirao M, Nishikawa K, Nagatsuma Y, Nakayama T, et al. Sarcopenia is associated with severe postoperative complications in elderly gastric cancer patients undergoing gastrectomy. Gastric Cancer. 2015. doi:10.1007/s10120-015-0546-4.
53. Tamandl D, Paireder M, Asari R, Baltzer PA, Schoppmann SF, Ba-Ssalamah A. Markers of sarcopenia quantified by computed tomography predict adverse long-term outcome in patients with resected oesophageal or gastro-oesophageal junction cancer. Eur Radiol. 2015. doi:10.1007/s00330-015-3963-1.
54. Cornet M, Lim C, Salloum C, Lazzati A, Compagnon P, Pascal G, et al. Prognostic value of sarcopenia in liver surgery. J Visc Surg. 2015. doi:10.1016/j.jviscsurg.2015.08.001.
55. Valentijn TM, Galal W, Tjeertes EK, Hoeks SE, Verhagen HJ, Stolker RJ. The obesity paradox in the surgical population. Surgeon. 2013;11(3):169–76. doi:10.1016/j.surge.2013.02.003.
56. Prado CM, Gonzalez MC, Heymsfield SB. Body composition phenotypes and obesity paradox. Curr Opin Clin Nutr Metab Care. 2015;18(6):535–51. doi:10.1097/mco.0000000000000216.
57. Cancello R, Clement K. Is obesity an inflammatory illness? Role of low-grade inflammation and macrophage infiltration in human white adipose tissue. BJOG. 2006;113(10):1141–7. doi:10.1111/j.1471-0528.2006.01004.x.
58. Bauer J, Capra S, Ferguson M. Use of the scored Patient-Generated Subjective Global Assessment (PG-SGA) as a nutrition assessment tool in patients with cancer. Eur J Clin Nutr. 2002;56(8):779–85. doi:10.1038/sj.ejcn.1601412.
59. Bruera E, Kuehn N, Miller MJ, Selmser P, Macmillan K. The Edmonton Symptom Assessment System (ESAS): a simple method for the assessment of palliative care patients. J Palliat Care. 1991;7(2):6–9.
60. Deutz NE, Safar A, Schutzler S, Memelink R, Ferrando A, Spencer H, et al. Muscle protein synthesis in cancer patients can be stimulated with a specially formulated medical food. Clin Nutr. 2011;30(6):759–68.
61. Winter A, MacAdams J, Chevalier S. Normal protein anabolic response to hyperaminoacidemia in insulin-resistant patients with lung cancer cachexia. Clin Nutr. 2012;31(5):765–73. doi:10.1016/j.clnu.2012.05.003.
62. MacDonald AJ, Johns N, Stephens N, Greig C, Ross JA, Small AC, et al. Habitual myofibrillar protein synthesis is normal in patients with upper GI cancer cachexia. Clin Cancer Res. 2015;21(7):1734–40. doi:10.1158/1078-0432.ccr-14-2004.
63. Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst. 1999;91(19):1616–34.
64. Morceau F, Dicato M, Diederich M. Pro-inflammatory cytokine-mediated anemia: regarding molecular mechanisms of erythropoiesis. Mediators Inflamm. 2009;2009:405016. doi:10.1155/2009/405016.
65. Benzing T, Brandes R, Sellin L, Schermer B, Lecker S, Walz G, et al. Upregulation of RGS7 may contribute to tumor necrosis factor-induced changes in central nervous function. Nat Med. 1999;5(8):913–8. doi:10.1038/11354.
66. Ferrando AA, Lane HW, Stuart CA, Davis-Street J, Wolfe RR. Prolonged bed rest decreases skeletal muscle and whole body protein synthesis. Am J Physiol. 1996;270(4 Pt 1):E627–33.
67. Murphy RA, Mourtzakis M, Chu QS, Reiman T, Mazurak VC. Skeletal muscle depletion is associated with reduced plasma (n-3) fatty acids in non-small cell lung cancer patients. J Nutr. 2010;140(9):1602–6. doi:10.3945/jn.110.123521.
68. Baracos VE. Regulation of skeletal-muscle-protein turnover in cancer-associated cachexia. Nutrition. 2000;16(10):1015–8.
69. Wang X, Hu Z, Hu J, Du J, Mitch WE. Insulin resistance accelerates muscle protein degradation: Activation of the ubiquitin-proteasome pathway by defects in muscle cell signaling. Endocrinology. 2006;147(9):4160–8. doi:10.1210/en.2006-0251.
70. Senn JJ, Klover PJ, Nowak IA, Mooney RA. Interleukin-6 induces cellular insulin resistance in hepatocytes. 2002. doi:10.2337/diabetes.51.12.3391.
71. Ozcan L, Ergin AS, Lu A, Chung J, Sarkar S, Nie D, et al. Endoplasmic reticulum stress plays a central role in development of leptin resistance. Cell Metab. 2009;9(1):35–51. doi:10.1016/j.cmet.2008.12.004.
72. Tilg H, Moschen AR. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol. 2006;6(10):772–83. doi:10.1038/nri1937.
73. Schaur RJ, Fellier H, Gleispach H, Fink E, Kronberger L. Tumor host relations. I. Increased plasma cortisol in tumor-bearing humans compared with patients with benign surgical diseases. J Cancer Res Clin Oncol. 1979;93(3):281–5.
74. Knapp ML, Al-Sheibani S, Riches PG, Hanham IW, Phillips RH. Hormonal factors associated with weight loss in patients with advanced breast cancer. Ann Clin Biochem. 1991;28(Pt 5):480–6.
75. Crown AL, Cottle K, Lightman SL, Falk S, Mohamed-Ali V, Armstrong L, et al. What is the role of the insulin-like growth factor system in the pathophysiology of cancer cachexia, and how is it regulated? Clin Endocrinol (Oxf). 2002;56(6):723–33.
76. Yoshikawa T, Noguchi Y, Doi C, Makino T, Nomura K. Insulin resistance in patients with cancer: relationships with tumor site, tumor stage, body-weight loss, acute-phase response, and energy expenditure. Nutrition. 2001;17(7–8):590–3.
77. World Health Organization. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser. 2000;894.